Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics (NASDAQ: ACRS) received FDA approval for an investigational new drug application to study ATI-450 in hospitalized COVID-19 patients. This Phase 2a trial, led by the University of Kansas Medical Center, aims to evaluate the efficacy of ATI-450 in mitigating cytokine release syndrome (CRS) in 36 patients. The study's primary endpoint is the proportion of patients free from respiratory failure by day 14. ATI-450 has shown potential in reducing multiple inflammatory cytokines, indicating its promise in addressing severe COVID-19 symptoms.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will provide a company overview, which can be accessed via a live audio webcast on Aclaris’ website, with an archived version available for 30 days. Aclaris is dedicated to treating immuno-inflammatory diseases, featuring a diverse portfolio that includes a late-stage drug candidate supported by a strong R&D initiative.
Aclaris Therapeutics reported financial results for Q1 2020, highlighting a net loss of $15.6 million, down from $37.6 million in Q1 2019.
Cash and equivalents rose to $79 million, with $11 million borrowed from Silicon Valley Bank to extend its cash runway into Q1 2022. The company resumed enrollment in its Phase 2a trial for ATI-450 amidst COVID-19 disruptions. R&D expenses decreased to $9.4 million, a drop of $10.2 million from the previous year, alongside a $1.8 million non-cash charge impacting financial results. Aclaris continues to seek partners for various product developments.